Clinical Trial Details
| Trial ID: | L0623 |
| Source ID: | NCT00772382 |
| Associated Drug: | Mci-196 |
| Title: | Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT00772382/results |
| Conditions: | Chronic Kidney Disease|Dialysis|Hyperphosphatemia |
| Interventions: | DRUG: MCI-196 |
| Outcome Measures: | Primary: Number of Adverse Events (AE), 52 weeks | Secondary: The Change in Serum Phosphorus From Baseline to Week 52, 52 weeks |
| Sponsor/Collaborators: | Sponsor: Mitsubishi Tanabe Pharma Corporation |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 116 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2008-12 |
| Completion Date: | 2010-08 |
| Results First Posted: | 2014-05-12 |
| Last Update Posted: | 2014-09-15 |
| Locations: | Los Angeles, California, United States|Orange, California, United States|Tarzana, California, United States|Orlando, Florida, United States|Pembroke Pines, Florida, United States|Atlanta, Georgia, United States|Gurnee, Illinois, United States|Evansville, Indiana, United States|Baton Rouge, Louisiana, United States|New Orleans, Louisiana, United States|Northport, New York, United States|Durham, North Carolina, United States|Oklahoma City, Oklahoma, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Burlington, Vermont, United States|Chesapeake, Virginia, United States|Kamloops, British Columbia, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada |
| URL: | https://clinicaltrials.gov/show/NCT00772382 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|